BioStem Technologies Statistics
Total Valuation
BioStem Technologies has a market cap or net worth of 248.98 million. The enterprise value is 238.84 million.
| Market Cap | 248.98M |
| Enterprise Value | 238.84M |
Important Dates
The next estimated earnings date is Tuesday, April 1, 2025.
| Earnings Date | Apr 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioStem Technologies has 16.65 million shares outstanding. The number of shares has increased by 47.46% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 16.65M |
| Shares Change (YoY) | +47.46% |
| Shares Change (QoQ) | -1.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 18.26 and the forward PE ratio is 7.40.
| PE Ratio | 18.26 |
| Forward PE | 7.40 |
| PS Ratio | 1.14 |
| PB Ratio | 10.69 |
| P/TBV Ratio | 11.08 |
| P/FCF Ratio | 17.05 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.50, with an EV/FCF ratio of 16.36.
| EV / Earnings | 15.07 |
| EV / Sales | 1.13 |
| EV / EBITDA | 10.50 |
| EV / EBIT | 10.64 |
| EV / FCF | 16.36 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.20.
| Current Ratio | 1.25 |
| Quick Ratio | 1.18 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 0.20 |
| Debt / FCF | 0.31 |
| Interest Coverage | 29.60 |
Financial Efficiency
Return on equity (ROE) is 164.25% and return on invested capital (ROIC) is 94.16%.
| Return on Equity (ROE) | 164.25% |
| Return on Assets (ROA) | 25.51% |
| Return on Invested Capital (ROIC) | 94.16% |
| Return on Capital Employed (ROCE) | 96.83% |
| Revenue Per Employee | 6.38M |
| Profits Per Employee | 480,427 |
| Employee Count | 33 |
| Asset Turnover | 3.83 |
| Inventory Turnover | 8.44 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +184.76% in the last 52 weeks. The beta is 1.45, so BioStem Technologies's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | +184.76% |
| 50-Day Moving Average | 14.55 |
| 200-Day Moving Average | 11.62 |
| Relative Strength Index (RSI) | 51.80 |
| Average Volume (20 Days) | 56,295 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.70 |
Income Statement
In the last 12 months, BioStem Technologies had revenue of 210.49 million and earned 15.85 million in profits. Earnings per share was 0.82.
| Revenue | 210.49M |
| Gross Profit | 199.65M |
| Operating Income | 22.45M |
| Pretax Income | 21.69M |
| Net Income | 15.85M |
| EBITDA | 22.67M |
| EBIT | 22.45M |
| Earnings Per Share (EPS) | 0.82 |
Balance Sheet
The company has 14.61 million in cash and 4.48 million in debt, giving a net cash position of 10.13 million or 0.61 per share.
| Cash & Cash Equivalents | 14.61M |
| Total Debt | 4.48M |
| Net Cash | 10.13M |
| Net Cash Per Share | 0.61 |
| Equity (Book Value) | 22.83M |
| Book Value Per Share | 1.40 |
| Working Capital | 20.37M |
Cash Flow
In the last 12 months, operating cash flow was 14.89 million and capital expenditures -295,252, giving a free cash flow of 14.60 million.
| Operating Cash Flow | 14.89M |
| Capital Expenditures | -295,252 |
| Free Cash Flow | 14.60M |
| FCF Per Share | 0.88 |
Margins
Gross margin is 94.85%, with operating and profit margins of 10.67% and 7.53%.
| Gross Margin | 94.85% |
| Operating Margin | 10.67% |
| Pretax Margin | 10.30% |
| Profit Margin | 7.53% |
| EBITDA Margin | 10.77% |
| EBIT Margin | 10.67% |
| FCF Margin | 6.94% |
Dividends & Yields
BioStem Technologies does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -47.46% |
| Shareholder Yield | -47.46% |
| Earnings Yield | 6.37% |
| FCF Yield | 5.86% |
Stock Splits
The last stock split was on January 27, 2015. It was a reverse split with a ratio of 0.0025.
| Last Split Date | Jan 27, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.0025 |
Scores
BioStem Technologies has an Altman Z-Score of 3.5.
| Altman Z-Score | 3.5 |
| Piotroski F-Score | n/a |